Deadly fungal infections are becoming resistant to common treatments, but a team of researchers from USC and from France have found a potential innovative solution.
Each year, invasive fungal infections sicken an estimated 2 million people worldwide and kill nearly 800,000 – but a team of international scientists have discovered a new approach for antifungal drug treatments.
Researchers from USC and France identified that a gene-regulating protein, Bdf1, is critical for the survival of the pathogenic fungus, Candida albicans.
“We have shown that Bdf1 is an important new target for drug design,” said Charles McKenna, a senior author of the study who is a professor of chemistry and pharmaceutical sciences in the USC Dornsife College of Letters, Arts and Sciences. “Our findings show that compounds that bind to this target will disrupt the growth of the fungus, opening the way to novel drug treatments for fungal disease.”
The French scientists who led the study with McKenna were Jérôme Govin and Carlo Petosa, both at the University of Grenoble Alpes.
Rising health threat
The fungus, C. albicans, is an aggressive pathogen that in healthy individuals is normally held in check by the immune system. However, people with a weakened immune system, including patients who have cancer, HIV or autoimmune diseases, are susceptible to the infection, which can be life-threatening, McKenna said.
The team’s findings, published on May 18 in the journal Nature Communications, may prove timely. Fungal infections such as candidiasis are increasingly resistant to drug treatments.
Each year, an estimated 46,000 patients in the United States become infected with invasive candidiasis, according to the Centers for Disease Control and Prevention.
“When susceptible people develop candida infections, the fungus may enter the bloodstream. If treatment is unsuccessful, it has a very high mortality rate – in the 40 percent range,” McKenna said. “We have a very limited number of drugs that are effective in treating such systemic infections. Unfortunately, like many other pathogens, C. albicans is increasingly resistant to the few available drugs, raising the stakes for patients, and fresh approaches are urgently needed.”
The Latest on: Antifungal drug treatments
- Europe's antifungal drugs market future investment opportunities forecast report scrutinized in new research on December 15, 2017 at 6:38 am
Europe Antifungal Drugs Market is estimated at $3.16 billion in 2016 and projected to grow with CAGR of 3.4% reaching $3.73 billion by 2021. In the following few years, the market is poised to grow hugely with the rising population globally. Antifungal ... […]
- Global Antifungal Drugs Market Share & Growth Rate Report 2017 on December 15, 2017 at 4:27 am
Antifungal drugs are used to cure fungal infections, which occur due to, unclean, unhygienic and damp environment. Fungal infections are caused by microscopic organisms invading epithelial tissue. Systemic fungal infections are usually caused by the ... […]
- FDA Launches New Tool for Sharing Information that Allows Doctors to Better Manage Antibiotic Use, Improve Patient Care on December 14, 2017 at 8:26 am
the U.S. Food and Drug Administration announced a new approach to get critical updates regarding antibiotics and antifungal drugs to health care professionals as part of an overall effort to combat antimicrobial resistance. The agency created a website ... […]
- FDA announces new approach for sharing updates on antibiotics, antifungal drugs to physicians on December 13, 2017 at 11:32 pm
Today the U.S. Food and Drug Administration is announcing a new approach to get critical updates regarding antibiotics and antifungal drugs to health care professionals as part of an overall effort to combat antimicrobial resistance. The agency created a ... […]
- BRIEF-FDA Creates Website For Information About When Infections Likely To Respond To Specific Drug on December 13, 2017 at 8:35 am
ANTIFUNGAL DRUGS TO HEALTH CARE PROFESSIONALS * FDA SAYS CREATED WEBSITE PROVIDING DIRECT & TIMELY ACCESS TO INFORMATION ABOUT WHEN BACTERIAL/FUNGAL INFECTIONS ARE LIKELY TO RESPOND TO A SPECIFIC DRUG Source text for Eikon: Our Standards:The Thomson ... […]
- Dermatology Drugs Market Research Report 2017-2025: By Drug Class, by Indications, by Geography and Company Profile on December 11, 2017 at 4:08 pm
drugs, and antifungal drugs. By disease indication the dermatology drugs market is segmented in to acne, psoriasis, actinic keratosis, rosacea, melanoma, rashes, scars, skin infections and dermatitis. In which acne is the most prominent segment to ... […]
- New Rapid City clinic puts generic drugs to use to help fight cancer on December 11, 2017 at 4:00 am
"These drugs sit there and languish ... Statins for treatment of high cholesterol, Mebendazole, an antifungal, and Doxycycline, an antibiotic. The research is incomplete, but all have shown promise, in different ways, in interrupting the supply of ... […]
- Research Report Explores the Asia-Pacific Topical Antifungal Drugs Market for the Forecast Period 2017 to 2022 on December 6, 2017 at 12:35 am
Worldwide Market Reports added Latest Research Report titled ” Asia-Pacific Topical Antifungal Drugs Market Report 2017 ” to its Large Report database. In this report, the Asia-Pacific Topical Antifungal Drugs market is valued at USD XX million in ... […]
- New atlas aims to improve diagnosis and treatment of life threatening fungal infections affecting 3 million Pakistanis on December 4, 2017 at 2:56 am
Many of the diagnostic tests that do exist are not available in developing countries, and well-established antifungal drugs that would cure disease are not reaching people that need them,” Professor Denning added. Speakers at the book launch ceremony on ... […]
via Google News and Bing News